TP53 and neoplasm: While highly expressed in NSCLC and associated with better survival rates, DMRTA2 demonstrates tumor-suppressive activity in wild-type p53 cells by competitively binding HSP90β at its N-terminal ATP-binding and middle domains, thereby inhibiting HSP90β-p53 interaction.